Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
15 Mar 24
DEFA14A
Additional proxy soliciting materials
15 Mar 24
DEF 14A
Definitive proxy
15 Mar 24
PRE 14A
Preliminary proxy
4 Mar 24
10-K
2023 FY
Annual report
20 Feb 24
8-K
Halozyme Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
20 Feb 24
8-K
Results of Operations and Financial Condition
17 Jan 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
Halozyme Reports Third Quarter 2023 Financial and Operating Results
6 Nov 23
8-K
Other Events
7 Sep 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Halozyme Reports Second Quarter 2023 Financial and Operating Results
8 Aug 23
UPLOAD
Letter from SEC
21 Jul 23
CORRESP
Correspondence with SEC
28 Jun 23
UPLOAD
Letter from SEC
14 Jun 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Halozyme Reports First Quarter 2023 Financial and Operating Results
9 May 23
8-K
Submission of Matters to a Vote of Security Holders
8 May 23
ARS
2022 FY
Annual report to shareholders
24 Mar 23
DEFA14A
Additional proxy soliciting materials
24 Mar 23
DEF 14A
Definitive proxy
24 Mar 23
8-K
Halozyme Provides Update on Licensee Co-formulation Patent Hearing In Europe
15 Mar 23
8-K
Other Events
13 Mar 23
8-K
Departure of Directors or Certain Officers
23 Feb 23
10-K
2022 FY
Annual report
21 Feb 23
8-K
Halozyme Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
21 Feb 23
8-K
Departure of Directors or Certain Officers
6 Feb 23
8-K
Halozyme Provides 2023 Financial Guidance and Outlook
10 Jan 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Halozyme Reports Third Quarter 2022 Financial and Operating Results
8 Nov 22
8-K
Entry into a Material Definitive Agreement
19 Aug 22
8-K
Entry into a Material Definitive Agreement
18 Aug 22
8-K
Halozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of
16 Aug 22
8-K
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million
15 Aug 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
Halozyme Reports Second Quarter 2022 Financial and Operating Results
9 Aug 22
8-K/A
Financial Statements and Exhibits
9 Aug 22
8-K
Halozyme Completes Antares Pharma Acquisition
24 May 22
SC TO-T/A
Third party tender offer statement (amended)
24 May 22
SC TO-T/A
Third party tender offer statement (amended)
12 May 22
Latest ownership filings
4
Michael J. LaBarre
26 Mar 24
4
Michael J. LaBarre
13 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
4
Michael J. LaBarre
28 Feb 24
144
Notice of proposed sale of securities
28 Feb 24
4
Michael J. LaBarre
27 Feb 24
4
Mark Howard Snyder
27 Feb 24
4
Nicole LaBrosse
27 Feb 24
4
Helen Torley
27 Feb 24
144
Notice of proposed sale of securities
27 Feb 24
4
Michael J. LaBarre
20 Feb 24
4
Mark Howard Snyder
20 Feb 24
4
Nicole LaBrosse
20 Feb 24
4
Helen Torley
20 Feb 24
4
Michael J. LaBarre
16 Feb 24
4
Nicole LaBrosse
16 Feb 24
4
Helen Torley
16 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
Michael J. LaBarre
13 Feb 24
4
Nicole LaBrosse
13 Feb 24
4
Helen Torley
13 Feb 24
SC 13G/A
Artisan Partners Limited Partnership
12 Feb 24
SC 13G/A
Invesco Ltd.
1 Feb 24
SC 13G/A
BlackRock Inc.
23 Jan 24
4
Michael J. LaBarre
18 Jan 24
144
Notice of proposed sale of securities
17 Jan 24
144
Notice of proposed sale of securities
16 Jan 24
4
Mark Howard Snyder
5 Jan 24
4
Michael J. LaBarre
13 Dec 23
144
Notice of proposed sale of securities
13 Dec 23
144
Notice of proposed sale of securities
12 Dec 23
4
Michael J. LaBarre
16 Nov 23
144
Notice of proposed sale of securities
15 Nov 23
144
Notice of proposed sale of securities
14 Nov 23
4
Michael J. LaBarre
17 Oct 23
144
Notice of proposed sale of securities
17 Oct 23
144
Notice of proposed sale of securities
19 Sep 23
4
Michael J. LaBarre
19 Sep 23
4
Helen Torley
31 Aug 23